Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Cagrilintide is a long-acting amylin analog peptide developed by Novo Nordisk for weight management research. It is studied as a once-weekly subcutaneous injection that may slow gastric emptying, reduce appetite, and improve glucose measures. Cagrilintide is investigational, not FDA-approved, and is often studied with semaglutide as CagriSema [1][2][3].
What is cagrilintide?
Cagrilintide is an investigational amylin analog peptide. Amylin is a natural hormone released by the pancreas with insulin after meals. It helps the brain sense fullness, slows food leaving the stomach, and helps smooth post-meal glucose changes [5]. Cagrilintide was engineered to last longer in the body, with a half-life of about 7 to 8 days in early human research, which supports weekly dosing in trials [2].
Who makes cagrilintide?
Cagrilintide is being developed by Novo Nordisk. The same company makes semaglutide, the generic name for the GLP-1 receptor agonist sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management in eligible patients [6][7]. Cagrilintide is also being studied in a fixed-dose combination with semaglutide called CagriSema, which remains investigational and is not FDA-approved [3].
How cagrilintide differs from natural amylin and pramlintide
Natural amylin can form clumps called amyloid fibrils, which makes it hard to use as a medicine. Pramlintide, sold as Symlin, is a first-generation amylin analog that is FDA-approved as an add-on to mealtime insulin in adults with type 1 or type 2 diabetes [8]. Pramlintide is short-acting and used around meals, while cagrilintide is designed for longer action in research settings [2]. Both amylin-pathway drugs can cause nausea, and pramlintide can increase severe low blood sugar risk when used with insulin [8].
How does cagrilintide work in the body?
Cagrilintide works mainly by activating amylin receptor and calcitonin receptor pathways linked to appetite control. In published research, these signals affect brain areas that help regulate fullness and food intake, including the hindbrain and hypothalamus [2][5]. These same pathways can also cause side effects, especially nausea and reduced appetite, so efficacy and tolerability are studied together over weekly trial dosing periods [1].
Action on amylin and calcitonin receptors
Cagrilintide is described as a non-selective amylin receptor agonist with calcitonin receptor activity [2]. That means it does not work like a GLP-1 receptor agonist. Instead, it uses amylin-related pathways that tell the brain the body has eaten enough [2][5]. In animal and human research, stronger appetite signaling is paired with gastrointestinal effects such as nausea and slower stomach emptying [1][2].
Slowed gastric emptying and satiety
One reason cagrilintide is studied for weight management is that amylin signaling can slow gastric emptying, meaning food leaves the stomach more slowly [5]. This may help people feel full sooner and stay full longer. The trade-off is that slower stomach emptying can also worsen nausea, bloating, constipation, or vomiting, especially during dose changes in trials [1].
Effects on blood sugar
Amylin helps reduce post-meal glucose spikes by slowing gastric emptying and reducing glucagon after meals [5]. Cagrilintide alone is not FDA-approved for diabetes, and it is not being presented here as a diabetes treatment [3]. In studies of CagriSema, the combination with semaglutide lowered HbA1c and fasting plasma glucose in adults with type 2 diabetes, while gastrointestinal side effects were also common [9].
What do clinical trials show about cagrilintide for weight loss?
Cagrilintide has shown dose-related weight loss in phase 2 research, but it remains investigational. In a 26-week phase 2 trial, adults with overweight or obesity received weekly cagrilintide research doses from 0.3 mg to 4.5 mg, placebo, or liraglutide 3.0 mg [1]. Higher cagrilintide doses led to larger average weight reductions, with nausea, constipation, decreased appetite, and vomiting among the common side effects [1]. Individual results vary.
Cagrilintide monotherapy results
In the phase 2 trial, the 2.4 mg cagrilintide research arm had about 10.8% mean body-weight reduction at 26 weeks, compared with about 3.0% with placebo and about 9.0% with liraglutide 3.0 mg [1]. This is a trial average, not a promise. The same trial reported more gastrointestinal side effects with cagrilintide than placebo, and people with certain histories, such as recent pancreatitis or severe gastrointestinal disease, were excluded [1].
CagriSema phase 1b and phase 2 data
CagriSema is the investigational co-formulation of cagrilintide plus semaglutide. In a phase 2 trial in people with type 2 diabetes, CagriSema lowered body weight and HbA1c compared with semaglutide, cagrilintide, or placebo over 32 weeks, with gastrointestinal side effects reported most often [9]. Novo Nordisk’s phase 3 REDEFINE and REIMAGINE programs are studying CagriSema for obesity, type 2 diabetes, and cardiovascular outcomes, but FDA review is not complete [3]. Individual results vary.
Is cagrilintide better than semaglutide?
There is no simple answer. Cagrilintide is an investigational amylin analog, while semaglutide is a GLP-1 receptor agonist available as FDA-approved brand products Ozempic and Wegovy, and also as compounded semaglutide through licensed 503A pharmacies when legally permitted [4][6][7]. Semaglutide has FDA-approved uses; cagrilintide does not [3][7]. Both can cause gastrointestinal side effects, and semaglutide carries label warnings and contraindications, including personal or family history of medullary thyroid carcinoma or MEN 2 [6][7].
| Feature | Cagrilintide | Semaglutide | CagriSema |
|---|---|---|---|
| Drug class | Investigational amylin analog with calcitonin receptor activity [2] | GLP-1 receptor agonist [6][7] | Investigational amylin analog + GLP-1 receptor agonist combination [3][9] |
| FDA status | Not FDA-approved for any indication [3] | Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management in eligible patients [6][7] | Not FDA-approved; phase 3 development is ongoing [3] |
| Route studied or labeled | Once-weekly subcutaneous injection in trials [1] | Once-weekly subcutaneous injection for Ozempic and Wegovy labels; oral semaglutide also exists for diabetes [6][7] | Once-weekly subcutaneous injection in trials [9] |
| Dose numbers from sources | In a 26-week phase 2 trial, cagrilintide arms studied 0.3 mg to 4.5 mg once weekly [1] | The FDA-approved Wegovy label includes titration to a maintenance dose of 2.4 mg once weekly [7] | In a phase 2 trial, CagriSema combined cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly under a research protocol [9] |
| Weight-loss evidence | About 10.8% mean weight reduction at 26 weeks in one 2.4 mg phase 2 research arm [1] | About 14.9% mean weight reduction at 68 weeks in STEP 1 for semaglutide 2.4 mg [10] | Combination studies report larger average effects than either pathway alone in studied groups, but the product remains investigational [3][9] |
| Common side effects | Nausea, constipation, decreased appetite, vomiting [1] | Nausea, vomiting, diarrhea, constipation, abdominal pain [6][7] | Overlapping gastrointestinal side effects [9] |
| Key cautions | Trial exclusions included some patients with pancreatitis history or severe gastrointestinal disease [1] | Contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2; pancreatitis and gallbladder warnings appear on labels [6][7] | Likely combines relevant cautions from both pathways; final FDA label does not exist yet [3][9] |
Mechanism: amylin analog vs GLP-1 receptor agonist
Semaglutide acts on the GLP-1 receptor. It increases glucose-dependent insulin release, reduces glucagon, slows gastric emptying, and affects appetite centers in the brain [6][7]. Cagrilintide acts through amylin and calcitonin receptor pathways [2]. These are different systems, which is why researchers study them together. The overlap is tolerability: both can cause nausea, vomiting, constipation, and reduced food intake [1][7].
Weight loss outcomes head-to-head
There are limited direct head-to-head data comparing cagrilintide with semaglutide. In separate trials, cagrilintide 2.4 mg produced about 10.8% mean weight reduction at 26 weeks, while semaglutide 2.4 mg produced about 14.9% mean weight reduction at 68 weeks in STEP 1 [1][10]. Cross-trial comparisons are imperfect because study designs and durations differ. Both medicines can cause side effects that may limit use [1][7].
Why the two are often combined
Cagrilintide and semaglutide are often studied together because they target different appetite and metabolic pathways [2][9]. The goal of research is additive weight reduction with tolerable side effects, but this must be tested in controlled trials. Combining pathways can also combine side effects, especially nausea, vomiting, constipation, dehydration risk, and slowed gastric emptying [1][7][9].
Can you take tirzepatide and cagrilintide together?
There are no large published human trials showing that tirzepatide and cagrilintide are safe or effective together. Tirzepatide is a GIP/GLP-1 dual agonist sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management; compounded tirzepatide may be prepared by licensed 503A pharmacies when legally permitted [4][11][12]. Cagrilintide is not FDA-approved, and combining it with tirzepatide outside a trial or clinician-directed protocol is off-label with unknown safety risks [3].
What preclinical data suggests
Preclinical work suggests that amylin-pathway signaling can complement incretin pathways such as GLP-1 and GIP/GLP-1 [5]. That does not prove human safety. When drugs share effects on appetite and gastric emptying, side effects may also add up, including nausea, vomiting, constipation, and dehydration risk [1][11][12].
Why combination peptide therapy is not a DIY decision
Combination peptide therapy can involve overlapping mechanisms, uncertain interactions, and changing legal access. Cagrilintide with tirzepatide is not an FDA-approved combination, and there is no standard FDA-approved dosing label for cagrilintide [3]. A licensed clinician must review medical history, contraindications, medications, pregnancy plans, side effects, and monitoring needs before considering any investigational or off-label approach.
What are the side effects of cagrilintide?
The most common cagrilintide side effects in published trials were gastrointestinal. In the 26-week phase 2 obesity trial, nausea, constipation, decreased appetite, and vomiting were reported more often with cagrilintide than placebo [1]. These side effects matter because they can affect hydration, nutrition, and whether a patient can stay on therapy. People with certain gastrointestinal or pancreas-related histories were excluded from trials, so real-world risk may differ [1].
Common gastrointestinal effects
Nausea is the key side effect to know. Constipation, vomiting, abdominal discomfort, and reduced appetite can also occur [1]. Similar gastrointestinal effects are seen with GLP-1 drugs like semaglutide and GIP/GLP-1 drugs like tirzepatide, so combining pathways may increase tolerability issues [7][11][12].
Titration and tolerability
Clinical trials often use gradual titration, meaning the studied dose is increased over time, to improve tolerability [1][9]. This article does not provide dosing instructions. Because cagrilintide has no FDA-approved label, there is no approved patient dosing schedule. Any use would require clinician evaluation, careful risk review, and monitoring.
How is cagrilintide dosed and given?
Cagrilintide dosing has only been studied in research protocols because the peptide is not FDA-approved. In published trials, it is given as a subcutaneous injection, meaning an injection under the skin, usually once weekly [1][2]. Trial protocols are not the same as patient instructions. There is no FDA-approved cagrilintide label, and this article does not recommend a dose.
Subcutaneous once-weekly injection
Published cagrilintide trials used once-weekly subcutaneous injections [1][2]. Subcutaneous medications are commonly injected into fatty tissue under the skin, but cagrilintide does not have FDA-approved patient instructions. Injection-site reactions can occur with peptide injections and should be part of a clinician-led risk discussion [1].
Dose ranges used in trials
In one phase 2 trial, participants received cagrilintide research doses ranging from 0.3 mg to 4.5 mg once weekly, and the 2.4 mg arm showed about 10.8% mean body-weight reduction at 26 weeks [1]. In a phase 2 CagriSema trial, participants received a co-formulation containing cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly under a research protocol [9]. These numbers are study data, not instructions for use.
Is cagrilintide FDA-approved, and how can patients access it?
Cagrilintide is not FDA-approved for any indication, and CagriSema remains investigational [3]. The most reliable access is through a registered clinical trial or a clinician evaluation when a legally permitted compounded option exists. Compounded cagrilintide via a licensed 503A pharmacy is not an FDA-approved drug; it is prepared for an individual patient based on a prescription, and availability can change with FDA policy, shortage status, ingredient rules, and state pharmacy law [4].
Regulatory status of brand cagrilintide and CagriSema
Brand cagrilintide and CagriSema have not completed FDA review [3]. The REDEFINE and REIMAGINE phase 3 programs are designed to study weight, glycemic, and cardiovascular outcomes, but a completed trial program does not guarantee approval [3]. FDA decisions depend on benefit, risk, manufacturing, labeling, and other review factors.
Compounded cagrilintide via 503A pharmacies
A 503A compounding pharmacy prepares patient-specific medications under a prescription when allowed by federal and state rules [4]. Compounded cagrilintide, if available, is not FDA-approved and does not have the same FDA-reviewed label as an approved brand drug [3][4]. Quality, sourcing, sterility, and state availability matter, so patients should use licensed pharmacies and clinician-supervised care.
Getting a clinician evaluation
If you are considering cagrilintide, compounded semaglutide, or compounded tirzepatide, the right first step is a clinical evaluation. Chia is one licensed telehealth option that can review eligibility for compounded weight-management therapies where legally permitted, but an individual clinician decides whether any prescription is appropriate. No website, pharmacy, or AI tool should replace medical judgment.
3-min quiz
Learn about clinician-reviewed options
A licensed clinician can review your health history, medications, goals, and contraindications before deciding whether any compounded or FDA-approved weight-management option is appropriate.
What peptides stack well with cagrilintide?
Cagrilintide stacking is mostly discussed with incretin medicines, not classic longevity peptides. These combinations are studied or discussed in clinical and research practice; they are not recommended protocols. No cagrilintide stack is FDA-approved, and combination-specific safety data are limited [3][9].
- Cagrilintide + semaglutide (CagriSema). Mechanistic rationale: amylin and GLP-1 pathways act on different appetite and metabolic signals, which may explain additive effects in studies [2][9]. Safety caveat: nausea, vomiting, constipation, dehydration risk, and slowed gastric emptying can overlap, and CagriSema remains investigational [3][9].
- Cagrilintide + tirzepatide. Mechanistic rationale: amylin signaling could complement GIP/GLP-1 signaling based on appetite biology [5]. Safety caveat: there are no large published human trials of this exact combination, and side effects may stack [11][12].
- Cagrilintide + pramlintide. Mechanistic rationale: both target the amylin pathway, so the overlap is high rather than clearly complementary [8]. Safety caveat: redundant mechanisms may increase nausea and other gastrointestinal effects, and pramlintide has specific severe hypoglycemia warnings when used with insulin [8].
Combination peptide therapy should not be treated as a do-it-yourself plan. A licensed clinician needs to assess contraindications, current medicines, lab history, side effects, pregnancy plans, and legal access before any investigational or off-label combination is considered.
Frequently asked questions
Cagrilintide may help reduce appetite, slow gastric emptying, and lower body weight in clinical trials [1][2]. In one phase 2 trial, the 2.4 mg research arm had about 10.8% mean weight reduction at 26 weeks [1]. The same studies reported gastrointestinal side effects such as nausea, constipation, decreased appetite, and vomiting [1]. Cagrilintide is not FDA-approved, and individual results vary [3].
No peptide selectively targets belly fat. FDA-approved GLP-1 and GIP/GLP-1 medications such as semaglutide and tirzepatide have evidence for total body-weight loss, which can include abdominal fat, but they also have side effects and contraindications on their labels [7][10][11][12]. Cagrilintide and CagriSema are still investigational [3].
Not clearly. Cagrilintide and semaglutide work through different pathways. Separate trials show about 10.8% mean weight reduction at 26 weeks for one cagrilintide research arm and about 14.9% mean weight reduction at 68 weeks for semaglutide 2.4 mg in STEP 1 [1][10]. Cross-trial comparisons are limited. Semaglutide has FDA-approved products; cagrilintide does not [3][7]. Both can cause gastrointestinal side effects.
There are no large published human trials proving this combination is safe or effective. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management in eligible patients, while cagrilintide is not FDA-approved [3][11][12]. Combining them outside a clinical trial or clinician-directed protocol is off-label and has unknown safety risks.
In a phase 2 trial, one cagrilintide 2.4 mg research arm showed about 10.8% mean body-weight reduction at 26 weeks [1]. Trial averages do not predict an individual person’s result. Side effects, dose changes, adherence, diet, activity, medical history, and other medicines can all affect outcomes. Individual results vary.
No. Cagrilintide is an amylin analog that acts through amylin and calcitonin receptor pathways [2]. GLP-1 receptor agonists, such as semaglutide, act on the GLP-1 receptor [7]. The two pathways may complement each other, but they can also have overlapping gastrointestinal side effects [1][7].
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still reviews each case, and the agent does not prescribe or decide eligibility.
3-min quiz
Talk with a licensed clinician
A clinician can help you compare FDA-approved and compounded options, review risks, and decide whether any prescription is appropriate for your health history.
References
- 1.Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino DM, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 2021.
- 2.Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Jensen CB, Galsgaard ED. Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry, 2021.
- 3.ClinicalTrials.gov. Research studies of CagriSema, cagrilintide, and semaglutide in obesity, type 2 diabetes, and cardiovascular outcomes, 2026.
- 4.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
- 5.Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews, 2015.
- 6.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2023.
- 7.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2024.
- 8.U.S. Food and Drug Administration. SymlinPen (pramlintide acetate) injection prescribing information, 2014.
- 9.Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Efficacy and safety of co-administered cagrilintide and semaglutide in type 2 diabetes: a randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 2023.
- 10.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 11.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2024.
- 12.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
